INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
20/05/2025
Voltar para busca
Dado oficial do USPTO
MABFC
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
33
Atualização mais recente
21/05/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
14/12/2016
Data de registro
06/03/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
20/09/2024
Última transação
21/05/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
FR
Examinador
POWERS, ALEXANDER
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the Greek letter delta to the left of the stylized term "MABFC", with the letters "M" and "F" capitalized and the remainder in lower case letters.
Titulares e representantes
Titulares
L. B. (pessoa física)
Representantes
Monte L. Falcoff/Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical products and preparations for the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; medicines for cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; protein supplements; diagnostic kits consisting primarily of monoclonal antibodies and fragment crystallizable proteins, buffers, and reagents for use in disease testing
Classe 42
Scientific and technological services, namely, scientific research and analysis in the field of monoclonal antibodies and fragment crystallizable proteins; design and development of medical products, namely, pharmaceutical compositions of monoclonal antibodies and fragment crystallizable proteins; scientific study and research in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; research and development in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; cellular and molecular biological research; design and development of medical products, namely, pharmaceutical compositions of monoclonal antibodies and fragment crystallizable proteins; testing, inspection or research of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; consulting in the field of medical research; engineering; genetic engineering; platform technology, namely, protein expression platform for research and development of pharmaceuticals; platform technology, namely, protein expression platform for manufacturing protein-based therapeutics; medical and scientific research of recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; laboratory services in the field of monoclonal antibodies
Publicações
Histórico de despachos e eventos da marca no USPTO.
33 publicações encontradas
C71T
CANCELLED SECTION 71
20/09/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/05/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
06/03/2023
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
26/04/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/04/2021
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
03/04/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/03/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
17/08/2018
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
08/06/2018
XXCR
GENERIC MADRID TRANSACTION CREATED
08/06/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/06/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
06/03/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/12/2017
PUBO
PUBLISHED FOR OPPOSITION
19/12/2017
GPNX
NOTIFICATION PROCESSED BY IB
15/12/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
29/11/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
29/11/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/11/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/11/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/11/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/11/2017
ALIE
ASSIGNED TO LIE
03/11/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/10/2017
RFNT
REFUSAL PROCESSED BY IB
03/06/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
18/05/2017
RFRR
REFUSAL PROCESSED BY MPU
18/05/2017
MAFR
APPLICATION FILING RECEIPT MAILED
12/05/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/05/2017
CNRT
NON-FINAL ACTION WRITTEN
10/05/2017
DOCK
ASSIGNED TO EXAMINER
08/05/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/05/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/05/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MABFC ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.